MDxHealth SA Ordinary Shares
MDXHStock
$0.43−79.86%52W
Market Cap$22.74M
P/E—
Div yield—
Beta0.62
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-96.32%
Price vs S&P 500 (4W)-18.88%
VGM Score53.57
Market Capitalization$22.74M
Earnings Surprise History
Q1 26-0.17est. -0.15
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.33
4.33
4.17
4.00
Industry Peers — Health Services(29)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MDXHMDxHealth SA Ordinary Shares | B | B | F | $0.43 |
| NTRANatera, Inc. Common Stock | F | A | B | $269.83 |
| DGXQuest Diagnostics Inc. | C | D | C | $209.41 |
| LHLabcorp Holdings Inc. | C | D | C | $281.94 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $155.00 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | B | $128.18 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $62.99 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.48 |
| VCYTVeracyte, Inc. | D | A | A | $59.22 |
| CELCCelcuity Inc. Common Stock | — | — | B | $88.29 |
About
MDxHealth SA develops molecular diagnostic tests for cancer using proprietary genomic and epigenetic technologies. Its tests help physicians diagnose urologic cancers and predict treatment response and recurrence risk. The company generates revenue through clinical laboratory services and by licensing its DNA methylation platform to partners. It operates in the United States and Europe.